Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition